万基遗传 MYGN 深 沪
等待开盘 12-19 09:30:00 美东时间
6.70
-0.250
-3.60%
华盛通- 最 高7.20
- 今 开7.03
- 成交量 75.97万股
- 最 低 6.615
- 昨 收 6.95
- 总市值 6.25亿
- 52周最高 15.47
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 3.76
- 委 比 86.35%
- 总股本 9321.37万
- 历史最高 50.44
- 量 比 0.85
- 振 幅 8.42%
- 历史最低 3.76
- 每 手 1
- 风险率 3.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
Myriad Genetics will present new data on its Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test at the 2025 San Antonio Breast Cancer Symposium. The Precise MRD Test, an ultrasensitive, second-generation pan-tumor MRD test, is particularly impactful for low-tumor-shedding cancers like breast cancer. The MyRisk Test has been expanded to include genes referenced in NCCN Guidelines and ASCO guidelines, supporting guide...
12-09 14:00
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
Clairity, Myriad Genetics, and MagView have formed a collaboration to improve breast cancer risk assessment by integrating genotype (Myriad’s MyRisk with RiskScore) and phenotype (Clairity Breast) data through MagView’s Luminary Risk platform. This partnership aims to better identify high-risk women without adding administrative burdens, offering a comprehensive and actionable risk view using AI-powered tools.
11-25 21:15
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that its management will participate in two upcoming healthcare conferences: the 7th Annual Wolfe Research Healthcare Conference on November 18, 2025, and the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025. Both events will include fireside chats available via live audio webcast on the investor information section of Myriad’s website.
11-11 14:00
QIAGEN Launches QIAsymphony Connect For Liquid Biopsy Workflows And Highlights HRD And CGP Innovations At AMP 2025
QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026QIAGEN showcases Sample to Insight workflows
11-10 14:39
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Myriad Genetics’ Earnings Call: Mixed Signals and Future Prospects
Myriad Genetics (($MYGN)) has held its Q3 earnings call. Read on for the main h...
11-05 08:28
Myriad Genetics Q3 Sales $205.700M Beat $204.897M Estimate
Myriad Genetics (NASDAQ:MYGN) reported quarterly sales of $205.700 million which beat the analyst consensus estimate of $204.897 million by 0.39 percent. This is a 3.56 percent decrease over sales of $213.300 million
11-04 05:08
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
